{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T08:42:15Z","timestamp":1780994535063,"version":"3.54.1"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"4-6","license":[{"start":{"date-parts":[[2008,12,1]],"date-time":"2008-12-01T00:00:00Z","timestamp":1228089600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr. Treat. Options in Oncol."],"published-print":{"date-parts":[[2008,12]]},"DOI":"10.1007\/s11864-009-0083-7","type":"journal-article","created":{"date-parts":[[2009,4,20]],"date-time":"2009-04-20T21:49:33Z","timestamp":1240264173000},"page":"277-287","source":"Crossref","is-referenced-by-count":37,"title":["Treatment of Advanced Thymoma and Thymic Carcinoma"],"prefix":"10.1007","volume":"9","author":[{"given":"Arun","family":"Rajan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Giaccone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2009,4,21]]},"reference":[{"issue":"8","key":"83_CR1","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1200\/JCO.1990.8.8.1419","volume":"8","author":"A Fornasiero","year":"1990","unstructured":"Fornasiero A, Daniele O, Ghiotto C et al. Chemotherapy of invasive thymoma. J Clin Oncol 1990; 8(8): 1419\u20131423.","journal-title":"J Clin Oncol"},{"issue":"2","key":"83_CR2","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1067\/mtc.2003.133","volume":"125","author":"MA Greene","year":"2003","unstructured":"Greene MA, Malias MA. Aggressive multimodality treatment of invasive thymic carcinoma. J Thorac Cardiovasc Surg 2003; 125(2): 434\u2013467. doi: 10.1067\/mtc.2003.133 .","journal-title":"J Thorac Cardiovasc Surg"},{"key":"83_CR3","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1634\/theoncologist.6-3-239","volume":"6","author":"SB Johnson","year":"2001","unstructured":"Johnson SB, Eng TY, Giaccone G, Thomas CR. Thymoma: Update for the new millennium. The Oncologist 2001; 6: 239\u2013246. doi: 10.1634\/theoncologist.6-3-239 .","journal-title":"The Oncologist"},{"key":"83_CR4","doi-asserted-by":"crossref","unstructured":"Masaoka A, Mondem Y, Nakahara K, et al.: Follow-up study of thymoma with special reference to their clinical stages. Cancer 1981; 48: 2485\u201392. doi: 10.1002\/1097-0142(19811201)48:11<2485::AID-CNCR2820481123>3.0.CO;2-R","DOI":"10.1002\/1097-0142(19811201)48:11<2485::AID-CNCR2820481123>3.0.CO;2-R"},{"key":"83_CR5","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/1010-7940(94)90155-4","volume":"8","author":"A Masaoka","year":"1994","unstructured":"Masaoka A, Yamakawa Y, Niwa H, et al. Thymectomy and malignancy. Eur J Cardiothoracic Surg 1994; 8: 251\u2013253. doi: 10.1016\/1010-7940(94)90155-4 .","journal-title":"Eur J Cardiothoracic Surg"},{"key":"83_CR6","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1002\/cncr.10226","volume":"94","author":"M Okumura","year":"2002","unstructured":"Okumura M, Onta M, Tateyama H, et al. The World Health Organization histologic classification system reflects the oncologic behavior of thymoma: a clinical study of 273 patients. Cancer 2002; 94: 624\u201332. doi: 10.1002\/cncr.10226 .","journal-title":"Cancer"},{"key":"83_CR7","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.hoc.2008.03.001","volume":"22","author":"S Suster","year":"2008","unstructured":"Suster S, Moran CA. Histologic classification of thymoma: the World Health Organization and beyond. Hematol Oncol Clin N Am 2008;22:381\u2013392. doi: 10.1016\/j.hoc.2008.03.001 .","journal-title":"Hematol Oncol Clin N Am"},{"key":"83_CR8","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1016\/S0003-4975(03)01139-1","volume":"76","author":"M Lopez-Cano","year":"2003","unstructured":"Lopez-Cano M, Ponseti-Bosch JM, Espin-Basany E, et al. Clinical and pathologic predictors of outcome in thymoma-associated myasthenia gravis. Ann Thorac Surg 2003; 76: 1643\u20131649. doi: 10.1016\/S0003-4975(03)01139-1 .","journal-title":"Ann Thorac Surg"},{"key":"83_CR9","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1016\/S0025-6196(12)60907-0","volume":"68","author":"TI Morgenthaler","year":"1993","unstructured":"Morgenthaler TI, Brown LR, Colby TV, et al. Thymoma. Mayo Clin Proc 1993; 68: 1110\u20131123.","journal-title":"Mayo Clin Proc"},{"key":"83_CR10","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1001\/archinte.1974.00320200184029","volume":"134","author":"JV Suadjian","year":"1974","unstructured":"Suadjian JV, Enriquez P, Siverstein MN, et al. The spectrum of diseases associated with thymoma: coincidence or syndrome? Arch Intern Med 1974; 134: 374\u2013379. doi: 10.1001\/archinte.134.2.374 .","journal-title":"Arch Intern Med"},{"issue":"3","key":"83_CR11","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.hoc.2008.03.004","volume":"22","author":"LM Tormoehlen","year":"2008","unstructured":"Tormoehlen LM, Pascuzzi RM. Thymoma, myastenia gravis, and other paraneoplastic syndromes. Hematol Oncol Clin North Am 2008;22(3):509\u2013526. doi: 10.1016\/j.hoc.2008.03.004 .","journal-title":"Hematol Oncol Clin North Am"},{"key":"83_CR12","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.critrevonc.2007.04.005","volume":"65","author":"CD Wright","year":"2008","unstructured":"Wright CD. Management of Thymomas. Critical Reviews in Oncology\/Hematology 2008; 65: 109\u2013120. doi: 10.1016\/j.critrevonc.2007.04.005 .","journal-title":"Crit Rev Oncol\/Hematol"},{"key":"83_CR13","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1016\/S0003-4975(03)00555-1","volume":"76","author":"K Kondo","year":"2003","unstructured":"Kondo K, Monden Y. Therapy for thymic epithelial tumors: a clinical study of 1320 patients from Japan. Ann Thorac Surg 2003; 76: 878\u201385. doi: 10.1016\/S0003-4975(03)00555-1 .","journal-title":"Ann Thorac Surg"},{"key":"83_CR14","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1097\/01.coc.0000227481.36109.e7","volume":"29","author":"G Giaccone","year":"2006","unstructured":"Giaccone G, Wilnik H, Paul MA, van der Valk P. Systemic treatment of malignant thymoma. Am J Clin Oncol 2006; 29: 336\u2013344. doi: 10.1097\/01.coc.0000227481.36109.e7 .","journal-title":"Am J Clin Oncol"},{"issue":"2","key":"83_CR15","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.athoracsur.2007.08.051","volume":"85","author":"CD Wright","year":"2008","unstructured":"Wright CD, Choi NC, Wain JC, et al. Induction chemoradiotherapy followed by resection for locally advanced Masaoka stage III and IVA thymic tumors. Ann Thorac Surg 2008; 85 (2): 385\u2013389. doi: 10.1016\/j.athoracsur.2007.08.051 .","journal-title":"Ann Thorac Surg"},{"key":"83_CR16","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/0003-4975(92)91391-L","volume":"54","author":"M Haniuda","year":"1992","unstructured":"Haniuda M, Morimoto M, Nishimura H, e al. Adjuvant radiotherapy after complete resection of thymoma. Ann Thorac Surg 1992; 54: 311\u2013315.","journal-title":"Ann Thorac Surg"},{"key":"83_CR17","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1200\/JCO.1994.12.6.1164","volume":"12","author":"PJ Loehrer","year":"1994","unstructured":"Loehrer PJ, Kim KM, Aisner SC, et al. Cisplatin plus doxorubicin plus cyclophosphamide in metastatic or recurrent thymoma: Final results of an Intergroup Trial. J Clin Oncol. 1994; 12: 1164\u20131168.","journal-title":"J Clin Oncol"},{"key":"83_CR18","doi-asserted-by":"crossref","unstructured":"Fornasiesro A, Daniele O, Ghiotto C, et al.: Chemotherapy for invasive thymoma: A 13\u00a0year experience. Cancer 1991; 68:30\u201333. doi: 10.1002\/1097-0142(19910701)68:1<30::AID-CNCR2820680106>3.0.CO;2-4","DOI":"10.1002\/1097-0142(19910701)68:1<30::AID-CNCR2820680106>3.0.CO;2-4"},{"key":"83_CR19","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1200\/JCO.1996.14.3.814","volume":"14","author":"G Giaccone","year":"1996","unstructured":"Giaccone G, Ardizzoni A, Kirkpatrick A, et al. Cisplatin and Etoposide combination chemotherapy for locally advanced or metastatic thymoma: A phase II study of the European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group. J Clin Oncol 1996; 14: 814\u2013820.","journal-title":"J Clin Oncol"},{"key":"83_CR20","doi-asserted-by":"crossref","unstructured":"Loehrer PJ, Jiroutek M, Aisner S, et al.: Combined Etoposide, ifosfamide and cisplatin in the treatment of patients with advanced thymoma and thymic carcinoma. An Intergroup Trial. Cancer 2001; 91: 2010\u20132015. doi: 10.1002\/1097-0142(20010601)91:11<2010::AID-CNCR1226>3.0.CO;2-2","DOI":"10.1002\/1097-0142(20010601)91:11<2010::AID-CNCR1226>3.0.CO;2-2"},{"key":"83_CR21","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1097\/JTO.0b013e31802bafc8","volume":"2","author":"K Yokoi","year":"2007","unstructured":"Yokoi K, Matsuguma H, Nakahara R, et al. Multidisciplinary Treatment for Advanced Invasive Thymoma with Cisplatin, Doxorubicin, and Methylprednisolone. J Thorac Oncol 2007; 2: 73\u201378. doi: 10.1097\/JTO.0b013e31802bafc8 .","journal-title":"J Thorac Oncol"},{"key":"83_CR22","doi-asserted-by":"crossref","unstructured":"Lemma GL, Loehrer PJ, Lee JW, et al.: A phase II study of carboplatin plus paclitaxel in advanced thymoma or thymic carcinoma: E1C99. J Clin Oncol 2008, ASCO Annual Meeting Proceedings; 26 [Abstract 8018]","DOI":"10.1200\/jco.2008.26.15_suppl.8018"},{"key":"83_CR23","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1002\/(SICI)1097-0142(19990501)85:9<1871::AID-CNCR1>3.3.CO;2-P","volume":"85","author":"M Hejna","year":"1999","unstructured":"Hejna M, Haberl I, Raderer M. Nonsurgical management of malignant thymoma. Cancer 1999; 85: 1871\u20131884.","journal-title":"Cancer"},{"issue":"4","key":"83_CR24","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1097\/00000421-199308000-00014","volume":"16","author":"PD Bonomi","year":"1993","unstructured":"Bonomi PD, Finkelstein D, Aisner S, Ettinger D. EST 2582 phase II trial of cisplatin in metastatic or recurrent thymoma. Am J Clin Oncol 1993; 16(4):342\u2013345. doi: 10.1097\/00000421-199308000-00014 .","journal-title":"Am J Clin Oncol"},{"key":"83_CR25","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1007\/s00432-004-0545-z","volume":"130","author":"JD Henley","year":"2004","unstructured":"Henley JD, Cummings OW, Loehrer PJ Sr. Tyrosine kinase receptor expression in thymomas. J Cancer Res Clin Oncol. 2004; 130: 222\u2013224. doi: 10.1007\/s00432-004-0545-z .","journal-title":"J Cancer Res Clin Oncol"},{"key":"83_CR26","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.canlet.2006.07.003","volume":"248","author":"M Meister","year":"2007","unstructured":"Meister M, Schirmacher P, Dienemann H, et al. Mutational status of the epidermal growth factor receptor (EGFR) gene in thymomas and thymic carcinomas. Cancer Lett. 2007; 248: 186\u2013191. doi: 10.1016\/j.canlet.2006.07.003 .","journal-title":"Cancer Lett"},{"key":"83_CR27","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1378\/chest.128.1.140","volume":"128","author":"K Nakagawa","year":"2005","unstructured":"Nakagawa K, Matsuno Y, Kunitoh H, et al. Immunohistochemical KIT (CD117) expression in thymic epithelial tumors. Chest 2005; 128: 140\u2013144. doi: 10.1378\/chest.128.1.140 .","journal-title":"Chest"},{"key":"83_CR28","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/S1470-2045(07)70141-9","volume":"8","author":"G Farina","year":"2007","unstructured":"Farina G, Garassino MC, Gambacorta M, et al. Response of thymoma to cetuximab. Lancet Oncol 2007; 8: 449\u2013450. doi: 10.1016\/S1470-2045(07)70141-9 .","journal-title":"Lancet Oncol"},{"key":"83_CR29","doi-asserted-by":"crossref","first-page":"757","DOI":"10.2741\/2098","volume":"12","author":"G Palmieri","year":"2007","unstructured":"Palmieri G, Marino M, Salvatore M, et al. Cetuximab is an active treatment of metastatic and chemorefractory thymoma. Front Biosci 2007; 12: 757\u2013761. doi: 10.2741\/2098 .","journal-title":"Front Biosci"},{"key":"83_CR30","doi-asserted-by":"crossref","unstructured":"Kurup A, Burns M, Dropcho S, et al.: Phase II study of gefitinib treatment in advanced thymic malignancies. J Clin Oncol 2005, ASCO Annual Meeting Proceedings; 23: [Abstract 7068]","DOI":"10.1200\/jco.2005.23.16_suppl.7068"},{"key":"83_CR31","doi-asserted-by":"crossref","unstructured":"Bedano PM, Perkins S, Burns M, et al.: A phase II trial of erlotinib plus bevacizumab in patients with recurrent thymoma or thymic carcinoma. J Clin Oncol 2008, ASCO Annual Meeting Proceedings; 26: [Abstract 19087]","DOI":"10.1200\/jco.2008.26.15_suppl.19087"},{"key":"83_CR32","doi-asserted-by":"crossref","first-page":"2625","DOI":"10.1056\/NEJM200406173502523","volume":"350","author":"P Strobel","year":"2004","unstructured":"Strobel P, Hautmann M, Jakob A, et al. Thymic carcinoma with overexpression of mutated KIT and the response to imatinib. N Eng J Med 2004; 350: 2625\u20132626. doi: 10.1056\/NEJM200406173502523 .","journal-title":"N Eng J Med"},{"key":"83_CR33","doi-asserted-by":"crossref","unstructured":"Giaccone G, Smit EF, van Groeningen C, Hogedoorn PC. Phase II study of imatinib in patients with WHO B3 and C thymomas. J Clin Oncol 2008, ASCO Annual Meeting Proceedings; 26: [Abstract 14665]","DOI":"10.1200\/jco.2008.26.15_suppl.14665"},{"key":"83_CR34","doi-asserted-by":"crossref","unstructured":"Salter JT, Lewis D, Yiannoutsos C, et al.: Imatinib for the treatment of thymic carcinoma. J Clin Oncol 2008, ASCO Annual Meeting Proceedings; 26: [Abstract 8116]","DOI":"10.1200\/jco.2008.26.15_suppl.8116"},{"key":"83_CR35","doi-asserted-by":"crossref","first-page":"e56","DOI":"10.1200\/JCO.2006.08.8963","volume":"24","author":"C Chuah","year":"2006","unstructured":"Chuah C, Lim TH, Lim AST, et al. Dasatinib induces a response in malignant thymoma. J Clin Oncol 2006; 24: e56-e58. doi: 10.1200\/JCO.2006.08.8963 .","journal-title":"J Clin Oncol"},{"key":"83_CR36","doi-asserted-by":"crossref","unstructured":"Suster S, Rosai J: Thymic carcinoma: a clinicopathologic study of 60 cases. Cancer 1991; 67: 1025\u20131032. doi: 10.1002\/1097-0142(19910215)67:4<1025::AID-CNCR2820670427>3.0.CO;2-F","DOI":"10.1002\/1097-0142(19910215)67:4<1025::AID-CNCR2820670427>3.0.CO;2-F"},{"key":"83_CR37","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1016\/j.ijrobp.2003.11.021","volume":"59","author":"TY Eng","year":"2004","unstructured":"Eng TY, Fuller CD, Jagirdar J, et al. Thymic carcinoma: state of the art review. Int J Radiat Oncol Biol Phys 2004; 59: 654\u2013664. doi: 10.1016\/j.ijrobp.2003.11.021 .","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"83_CR38","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1002\/ijc.11101","volume":"105","author":"R Penzel","year":"2003","unstructured":"Penzel R, Hoegel J, Schmitz W, et al. Clusters of chromosomal imbalances in thymic epithelial tumors are associated with the WHO classification and the staging system according to Masaoka. Int J Cancer 2003; 105: 494\u2013498. doi: 10.1002\/ijc.11101 .","journal-title":"Int J Cancer"},{"key":"83_CR39","first-page":"3708","volume":"63","author":"M Inoue","year":"2003","unstructured":"Inoue M, Starostik P, Zettl A, et al. Correlating genetic abnormalities with World Health Organization-defined histology and stage across the spectrum of thymomas. Cancer Res 2003; 63: 3708\u20133715.","journal-title":"Cancer Res"},{"key":"83_CR40","doi-asserted-by":"crossref","unstructured":"WeideLG, Ulbright TM, Loehrer PJ Sr, Williams SD: Thymic carcinoma. A distinct clinical entity responsive to chemotherapy. Cancer 1993;71(4): 1219\u20131223. doi: 10.1002\/1097-0142(19930215)71:4<1219::AID-CNCR2820710408>3.0.CO;2-B","DOI":"10.1002\/1097-0142(19930215)71:4<1219::AID-CNCR2820710408>3.0.CO;2-B"},{"key":"83_CR41","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/S1010-7940(01)00666-2","volume":"19","author":"M Lucchi","year":"2001","unstructured":"Lucchi M, Mussi A, Basolo F, et al. The multimodality treatment of thymic carcinoma. Eur J Cardiothorac Surg 2001; 19: 566\u2013569. doi: 10.1016\/S1010-7940(01)00666-2 .","journal-title":"Eur J Cardiothorac Surg"},{"key":"83_CR42","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.lungcan.2007.05.016","volume":"59","author":"E Magois","year":"2008","unstructured":"Magois E, Guigay J, Blancard PS, et al. Multimodal treatment of thymic carcinoma: Report of nine cases. Lung Cancer 2008; 59: 126\u2013132. doi: 10.1016\/j.lungcan.2007.05.016 .","journal-title":"Lung Cancer"},{"key":"83_CR43","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1097\/01.coc.0000046301.83671.09","volume":"27","author":"FJ Hernandez-Ilizaliturri","year":"2004","unstructured":"Hernandez-Ilizaliturri FJ, Tan D, Cipolla D, et al. (2004) Multimodality therapy for thymic carcinoma (TCA) Results of a 30-year single-institution experience. Am J Clin Oncol 27: 68\u201372. doi: 10.1097\/01.coc.0000046301.83671.09 .","journal-title":"Am J Clin Oncol"},{"key":"83_CR44","doi-asserted-by":"crossref","unstructured":"Huang J, Rizk N, Park B, et al.: Recent clinical experience with multimodality therapy in thymic carcinoma. J Clin Oncol 2007, ASCO Annual Meeting Proceedings; 25: [Abstract 18003]","DOI":"10.1200\/jco.2007.25.18_suppl.18003"},{"key":"83_CR45","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1053\/j.semtcvs.2004.12.004","volume":"17","author":"AM Ciccone","year":"2005","unstructured":"Ciccone AM, Rendina EA. Treatment of Recurrent Thymic Tumors. Semin Thorac Cardiovasc Surg 2005; 17: 27\u201331. doi: 10.1053\/j.semtcvs.2004.12.004 .","journal-title":"Semin Thorac Cardiovasc Surg"},{"key":"83_CR46","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1200\/JCO.2004.02.047","volume":"22","author":"PJ Loehrer","year":"2004","unstructured":"Loehrer PJ, Wang W, Johnson DH, Ettinger DS. Octreotide alone or with Prednisone in Patients with Advanced Thymoma and Thymic Carcinoma. An Eastern Cooperative Oncology Group Phase II Trial. J Clin Oncol 2004; 22: 293\u2013299. doi: 10.1200\/JCO.2004.02.047 .","journal-title":"J Clin Oncol"},{"key":"83_CR47","doi-asserted-by":"crossref","unstructured":"Loehrer PJ, Yiannoutsos CT, Dropcho S, et al.: A phase II trial of pemetrexed in patients with recurrent thymoma or thymic carcinoma. J Clin Oncol 2006, ASCO Annual Meeting Proceedings; 24: [Abstract 7079]","DOI":"10.1200\/jco.2006.24.18_suppl.7079"},{"issue":"7","key":"83_CR48","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1093\/jjco\/hyf059","volume":"32","author":"S Umemura","year":"2002","unstructured":"Umemura S, Segawa Y, Fujiwara K, et al. A case of recurrent metastatic thymoma showing a marked response to paclitaxel monotherapy. Jpn J Clin Oncol 2002;32(7):262\u2013265. doi: 10.1093\/jjco\/hyf059 .","journal-title":"Jpn J Clin Oncol"},{"key":"83_CR49","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1159\/000082626","volume":"50","author":"T Oguri","year":"2004","unstructured":"Oguri T, Achiwa H, Kato D, et al. Efficacy of docetaxel as a second-line chemotherapy for thymic carcinoma. Chemotherapy 2004;50:279\u2013282. doi: 10.1159\/000082626 .","journal-title":"Chemotherapy"},{"key":"83_CR50","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.ejcts.2008.01.015","volume":"33","author":"M Lucchi","year":"2008","unstructured":"Lucchi M, Basolo F, Mussi A. Surgical treatment of pleural recurrence from thymoma. Eur J Cardiothorac Surg 2008; 33: 707\u2013711. doi: 10.1016\/j.ejcts.2008.01.015 .","journal-title":"Eur J Cardiothorac Surg"},{"key":"83_CR51","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1097\/JTO.0b013e31815e8b73","volume":"3","author":"C Sugie","year":"2008","unstructured":"Sugie C, Shibamoto Y, Ikeya-Hashizuma C, et al. Invasive thymoma: postoperative mediastinal irradiation, and low-dose entire hemithorax irradiation in patients with pleural dissemination. J Thorac Oncol 2008; 3: 75\u201381. doi: 10.1097\/JTO.0b013e31815e8b73 .","journal-title":"J Thorac Oncol"},{"key":"83_CR52","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1378\/chest.121.2.480","volume":"121","author":"E DeBree","year":"2002","unstructured":"DeBree E, van Ruth S, Baas P, et al. Cytoreductive surgery and intraoperative hyperthermic intrathoracic chemotherapy in patients with malignant pleural mesothelioma or pleural metastases of thymoma. Chest 2002; 121: 480\u2013487. doi: 10.1378\/chest.121.2.480 .","journal-title":"Chest"}],"container-title":["Current Treatment Options in Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-009-0083-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11864-009-0083-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-009-0083-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,17]],"date-time":"2020-05-17T16:37:38Z","timestamp":1589733458000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11864-009-0083-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,12]]},"references-count":52,"journal-issue":{"issue":"4-6","published-print":{"date-parts":[[2008,12]]}},"alternative-id":["83"],"URL":"https:\/\/doi.org\/10.1007\/s11864-009-0083-7","relation":{},"ISSN":["1527-2729","1534-6277"],"issn-type":[{"value":"1527-2729","type":"print"},{"value":"1534-6277","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,12]]}}}